Phase 1Completed

Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

Effects of GSK3640254 on the Single-Dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects

Sponsor
ViiV Healthcare (Industry)
Enrollment
20 enrolled
Conditions
HIV Infections
Interventions
GSK3640254 200 mg; Caffeine 200 mg; Metoprolol 100 mg; Montelukast 10 mg; Flurbiprofen 100 mg; Omeprazole 40 mg; Midazolam 5 mg (2.5 mL); Digoxin 0.25 mg; Pravastatin 40 mg
Ages
adults
Registry
NCT04425902

Full record on ClinicalTrials.gov

From the registry

This is an open-label, single sequence study that is being conducted to investigate the potential drug-drug interaction (DDI) when GSK3640254 is co-administered with a cocktail of cytochrome P450 (CYP) enzymes and transporter probe substrates in healthy participants. This study will aid in understanding these interactions and resulting changes in exposure (if any) when drugs that are metabolized via these pathways are given in combination with GSK3640254. The study will consist of a Screening period and 3 sequential treatment regimens. Participants will be administered a single dose of probe substrate drugs (caffeine 200 milligram (mg), metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg and pravastatin 40 mg) on Day 1. Participants will then receive GSK3640254 200 mg once daily on Days 11 to 20 followed by co-administration of probe substrate drugs with GSK3640254 on Day 21.

Primary outcomes

  • Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine
  • AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for Caffeine
  • Maximum Observed Plasma Concentration (Cmax) for Caffeine
  • Time to Cmax (Tmax) for Caffeine

History

  1. Last registry update

  2. Results first posted

  3. Primary completion

  4. Started

  5. Registered